About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

About Disclosure UK

Disclosure UK is a searchable database, published on the ABPI’s website, detailing ‘transfers of value’ – payments and benefits in kind made to UK HCPs and HCOs by pharmaceutical companies.

The database, launched in June 2016, is updated annually with the previous year’s disclosures and contains details of certain payments and other benefits in kind made to HCPs unless there is a legal reason why a particular HCP cannot be individually named.

The annual publication of this data on Disclosure UK is a requirement of the ABPI’s Code of Practice for the Pharmaceutical Industry. It is part of a Europe-wide transparency initiative spanning 33 countries, which are all making these payments and benefits in kind public every year.

¹Research and development activities

Individual company spending on research and development activities related to healthcare professionals and healthcare organisations is disclosed in aggregate.

Clause 23.2 Research and Development Transfers of Value, of the ABPI Code of Practice for the Pharmaceutical Industry 2016 includes:

For the purpose of disclosure, the aggregate research and development transfers of value are transfers of value to health professionals or healthcare organisations related to the planning or conduct of:

  • Non-clinical studies (as defined in the OECD Principles of Good Laboratory Practice)
  • Clinical trials (as defined in Directive 2001/20/EC)
  • Non-interventional studies that are prospective in nature and involve the collection of data from, or on behalf of individual or groups of health professionals specifically for the study.

Costs that are subsidiary to these activities can be included in the aggregate amount.

In other words, this includes payments to healthcare organisations for health professionals in the NHS to carry out clinical research on behalf of industry.

The spend on research and development activities disclosed in aggregate today reflects just a proportion of the pharmaceutical industry’s overall investment in scientific research. The pharmaceutical industry currently invests more money into research and development than any other industry in the UK. In 2016 the industry invested £4.2 billion (http://bit.ly/2uqEAjb) in the development of effective life-enhancing medicines.

This figure includes the majority of the costs associated with discovering and developing new medicines and enhancing existing medicines. This includes:

  • Pharmaceutical company-employed scientific and administrative staff
  • Buildings and physical equipment
  • The costs of in-company scientific and medical exploration
  • Engagement with academics and other institutions for early phases exploration on how diseases work

²Joint Working

Joint Working describes situations where, for the benefit of patients, the NHS and industry organisations pool skills, experience and/or resources for the joint development and implementation of patient centred projects and share a commitment to successful delivery.

RAND Europe guidance notes

Data from Disclosure UK (2015, 2016 and 2017) is available to download in Excel for comprehensive analysis. To accurately analyse the data available and understand what conclusions can and cannot be drawn, a set of guidance notes from RAND Europe accompanies each set of data.

Media enquiries

+44 (0) 20 7747 7147​​